October 2, 2024 – Page 7

Ladybug Surpasses $6 Million in Revenue for First Half of Year

Written by Customer Service on October 2, 2024. Posted in Earnings Releases And Operating Results.

TULSA, Okla., Oct. 02, 2024 (GLOBE NEWSWIRE) — Ladybug Resource Group, Inc. (OTC PINK: LBRG), also known as Ladybug NutraTech, reported revenues of $6.0 million USD for the six months ending June 30, 2024, reflecting an impressive increase of approximately $2.8 million USD compared to total revenues generated in 2023. Ladybug Resource Group’s strategic initiatives for 2024, operating under the brand name Ladybug NutraTech, include the acquisition of profitable websites, expansion of product lines, and growth of the customer base. These initiatives are clearly reflected in the Company’s Q1 and Q2 revenue results. The development and optimization of e-commerce platforms have driven significant revenue growth, resulting in an approximately 84% increase compared to total revenues in 2023. This consistent upward trend highlights...

Outbrain Launches “Moments”: A Next-Generation Immersive Video Experience for the Open Internet

Written by Customer Service on October 2, 2024. Posted in Public Companies.

New Solution Delivers Greater Engagement for Publishers and Opportunity for Brands to Drive More Attention NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) — Outbrain (NASDAQ: OB), a leading technology platform that drives business results across the open internet, today announced the beta launch of Moments by Outbrain – a new way for users to interact with content, delivering the immersive experience of full screen vertical video browsing to the open internet. Moments enables traditional publishers and media owners to reimagine their online experience by transforming real estate on static articles into engaging vertical video feeds, bringing easy swipeable navigation to trusted, professional environments. Audiences are spending an increasing amount of their time within walled gardens and social platforms. Moments marks the development...

Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema MINNEAPOLIS, Oct. 02, 2024 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and...

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Written by Customer Service on October 2, 2024. Posted in Public Companies.

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. Chris Gibson, Ph.D., Co-founder and CEO of Recursion said, “REC-1245 is a prime example...

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Written by Customer Service on October 2, 2024. Posted in Public Companies.

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88% (15/17) of patients had a complete metabolic responseIMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune® HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology (ASTRO) Annual...

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Written by Customer Service on October 2, 2024. Posted in Public Companies.

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more...

Primech Secures Major New Contracts, Paving the Way for Future Growth

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Total Value Exceeding SG$5.6 million (US$4.3 million) SINGAPORE, Oct. 02, 2024 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company”), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, is excited to announce several newly signed contracts, signaling robust growth and expanding opportunities across multiple sectors. With a total value exceeding SG$5.6 million (US$4.3 million), these new agreements underscore Primech’s ongoing commitment to delivering exceptional facility services that consistently exceed each client’s and sector’s unique demands. The latest contract wins include: Secured a 5-year contract valued at SG$4.59 million (US$3.54 million) for cleaning and pest control services...

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications” BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John Alam, Chief Executive Officer, is scheduled to participate in a panel discussion and one-on-one investor meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, being held in New York, NY, on October 9, 2024. Panel DetailsTitle: “Opportunities and Challenges When Small Names Go After Blockbuster Indications”Date: Wednesday, October 9, 2024Time: 8:00am ET About CervoMedCervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The...

Golden Matrix Group Inc. Announces Additional Amendment to Earnout Structure of Share Purchase Agreement With Subsidiary Meridianbet

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Golden Matrix Group Inc, Meridianbet Management Converts Cash Earnout Payments to Golden Matrix Common Stock, Highlighting Confidence in Company’s Financial Position and Financial Performance LAS VEGAS, Oct. 02, 2024 (GLOBE NEWSWIRE) — Golden Matrix Group Inc. (NASDAQ: GMGI) (“GMGI” or “the Company”) announces that on 1st October 2024, the Company passed its fifth amendment to the initial share purchase agreement (the “Share Purchase Agreement”) with Meridianbet in connection with the Company’s previous acquisition of Meridianbet earlier this year. Under the current Purchase Agreement, Golden Matrix is obligated to pay Aleksandar Milovanović, Zoran Milošević and Snežana Božović (the “Sellers”) additional sums of cash and Golden Matrix Common Stock within five business days following October 9, 2024. As of 1st October 1,...

AMERICAN REBEL HOLDINGS, INC. (NASDAQ: AREB) ANNOUNCES EFFECTIVENESS OF 1-FOR-9 REVERSE STOCK SPLIT AT THE OPEN OF TRADING ON OCTOBER 2, 2024

Written by Customer Service on October 2, 2024. Posted in Public Companies.

Nashville, TN, Oct. 02, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) — America’s Patriotic Brand (the “Company”), today announced the effectiveness of its 1-for-9 reverse stock split of its outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), as of 12:00 a.m. on October 2, 2024. The Company’s Common Stock will begin trading on a reverse stock split-adjusted basis at the opening of the Nasdaq Capital Market (“Nasdaq”) on Wednesday, October 2, 2024. Following the reverse stock split, the Common Stock will continue to trade on Nasdaq under the symbol “AREB” with the new CUSIP number, 02919L505. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on Nasdaq. Key...

Day: October 2, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice